Biomea Fusion, Inc. BMEA 深 滬
等待開盤 11-06 09:30:00 美东时间
1.34
+0.080
+6.35%
華盛通- 最 高1.355
- 今 開1.25
- 成交量 90.95万股
- 最 低 1.2205
- 昨 收 1.26
- 總市值 7974.14万
- 52周最高 7.50
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.2205
- 委 比 -80.37%
- 總股本 5950.85万
- 歷史最高 43.69
- 量 比 0.78
- 振 幅 10.67%
- 歷史最低 1.2205
- 每 手 1
- 風險率 1.74%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
今天 09:55
D. Boral Capital Maintains Buy on Biomea Fusion, Lowers Price Target to $12
D. Boral Capital analyst Jason Kolbert maintains Biomea Fusion (NASDAQ:BMEA) with a Buy and lowers the price target from $16 to $12.
11-05 21:39
Biomea Fusion Q3 EPS $(0.27) Misses $(0.26) Estimate
Biomea Fusion (NASDAQ:BMEA) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.26) by 2.27 percent. This is a 70.33 percent increase over losses of $(0.91) per share from
11-05 05:46
Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights
Biomea Fusion reported third-quarter financial results and business updates, highlighting advancements in its icovamenib and BMF-650 programs for diabetes and obesity. Icovamenib demonstrated durable 52-week Phase II data, with significant HbA1c reductions and favorable safety profiles. BMF-650 initiated its Phase I trial, targeting obesity. The company raised $68 million, extending its cash runway into Q1 2027. Operating expenses decreased by ov...
11-04 21:05
Biomea Fusion’s BMF-650: A New Hope in Obesity Treatment?
Biomea Fusion Inc (($BMEA)) announced an update on their ongoing clinical study...
11-01 00:30
Biomea Fusion to Present Poster Presentations at ObesityWeek®2025
Biomea Fusion, Inc. will present preclinical data for BMF-650, an oral GLP-1 receptor agonist, and combination data for icovamenib with semaglutide at ObesityWeek® 2025. BMF-650 and icovamenib are part of Biomea’s portfolio targeting diabetes and obesity. The abstracts will be published in the Obesity journal supplement.
10-30 12:00
Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist
<p>Biomea Fusion公司宣布，其用于治疗肥胖的下一代口服小分子GLP-1受体激动剂BMF-650已进入一期临床试验。首位患者已接受剂量，预计2026年上半年公布初期数据。在肥胖猴子模型中，BMF-650展示了显著的体重减轻和食物摄入减少，且耐受性良好。公司期望BMF-650凭借更高的生物利用度和一致的血浆暴露，为肥胖患者提供更有效的代谢效益。</p>
10-27 12:00
Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series
Biomea Fusion will participate in Citi’s SMID Biotech fireside chat on October 23. The event will be live streamed with a replay available afterward. Biomea, focused on diabetes and obesity therapies, is developing icovamenib and BMF-650 to address metabolic disorders. Visit their website or follow them on LinkedIn, X, and Facebook for updates.
10-21 23:05
Nasdaq Tumbles 200 Points; Trilogy Metals Shares Spike Higher
U.S. stocks traded lower midway through trading, with the Nasdaq Composite fall...
10-08 00:29
Dow Jumps Over 100 Points; McCormick Earnings Top Views
U.S. stocks traded higher this morning, with the Dow Jones index gaining more t...
10-07 22:20
